Immunic (NASDAQ: IMUX) is one of 582 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Immunic to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.
Insider and Institutional Ownership
45.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 67.9% of Immunic shares are owned by company insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Immunic has a beta of 3.59, meaning that its share price is 259% more volatile than the S&P 500. Comparatively, Immunic’s rivals have a beta of 1.21, meaning that their average share price is 21% more volatile than the S&P 500.
This table compares Immunic and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Immunic and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunic Competitors||$2.13 billion||$224.57 million||-3.40|
Immunic’s rivals have higher revenue and earnings than Immunic. Immunic is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations for Immunic and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunic currently has a consensus price target of $40.00, indicating a potential upside of 180.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 63.31%. Given Immunic’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunic is more favorable than its rivals.
Immunic beats its rivals on 8 of the 13 factors compared.
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.